Newcastle University

Dr Barbara Durkacz
Prof of Experimental Cancer Therapeutics

• Email: b.w.durkacz@ncl.ac.uk
• Telephone: +44 (0) 191 222 4413
• Fax: +44 (0) 191 222 7556
• Address: Northern Institute for Cancer Research
  School of Clinical & Laboratory Sciences
  Medical School
  University of Newcastle upon Tyne
  NE2 4HH

Selected Publications

• Veuger, S.J.; Curtin, N.J.; Smith, G.; Durkacz, B.W. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004, 23(44), 7322-7329.
• Willmore, E.; De Caux, S.; Sunter, N.; Tilby, M.J.; Jackson, G.; Austin, C.; Durkacz, B.W. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004, 103(12), 4659-4665.
• Calabrese C; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford I; Skalitzky D; Thomas HD; Wang L; Webber S; Almassy R; William K; Curtin NJ; Barton S; Batey M; Calvert AH; Canan-Koch S; Durkacz B; Hostomsky Z; Kumpf R. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96(1), 56-67.
• Calabrese C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ; Batey M; Thomas HD; Durkacz B; Wang L; Kyle S; Skalitzky D; Li J; Zhang C. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies. Clinical Cancer Research 2003, 9(7), 2711-2718.
• Veuger, S.; Curtin, N.J.; Richardson, C.; Smith, G.; Durkacz, B.W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Research 2003, 63(18), 6008-6015.
• Delaney, C.A.; Wang, L.; Kyle, S.; White, A.W.; Calvert, A.H.; Curtin, N.J.; Durkacz, B.W.; Hostomsky, Z; Newell, D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical Cancer Research 2000, 6(7), 2860-2867.

More Publications